

Higher co-payments increase chance of early discontinuation of breast cancer therapy

December 11 2010

A higher prescription co-payment, especially among older women, is associated with both early discontinuation and incomplete use of adjuvant aromatase inhibitor therapy, a life-saving therapy for women with hormone sensitive early stage breast cancer.

Dawn L. Hershman, MD, associate professor of medicine and epidemiology and co-director of the [Breast Cancer](#) Program at the Herbert Irving Comprehensive Cancer Center at Columbia University, will be presenting detailed study results at The 33rd CTBC-AACR San Antonio Breast Cancer Symposium, a comprehensive scientific meeting covering the full spectrum of breast cancer research. Approximately 9,000 participants from more than 90 countries are expected to attend the symposium, Dec. 8-12, 2010.

Previous research has identified several factors affecting patient compliance with use of adjuvant [aromatase inhibitors](#), such as young and old age, severity of side effects and belief that the medication is useful.

Dr. Hershman and colleagues examined the impact of prescription co-payments on hormone therapy use. Working with the Medco Research Institute, a wholly owned subsidiary of Medco Health Solutions, Inc., de-identified patient information was used to target women older than 50 years who were prescribed aromatase inhibitors for early breast cancer.

"We looked at two different factors: women who discontinued use altogether or had no subsequent refills and those that did not refill their

prescription on time or did not take the medication at least 80% of the time," said Dr. Hershman.

Results showed that of the 8,110 women aged 50 to 65 years, 21.1 percent stopped taking the medication and of those who properly continued with their regimen 10.3 percent did not take the medication as directed over the two-year period. Of the 14,050 women 65 years or older, almost 25 percent stopped taking the medication and of those who continued, 8.9 percent were non-adherent.

Co-payments were categorized as less than \$30, between \$30 and \$89.99, and \$90 or more. The 90-day co-payments ranged from \$0 to \$893.49.

In the 65 and older group, women were more likely to discontinue medication use if they fell in the co-payment categories above \$30. However, in the under 65 age group co-payments needed to reach \$90 or more before they were more likely to discontinue use or not take it as prescribed.

Additionally, the study results showed that women whose prescriptions came from a primary care doctor or [women](#) who were prescribed many other medications were also more likely to stop taking the medications or not take it as prescribed.

"When we have highly effective medications available, we need to try to set limits on potential barriers to use like co-payments," said Dr. Hershman. Based on these findings, "future public policy efforts should be directed towards reducing financial constraints as a means of increasing the complete use of these life-saving medications."

"While high co-payments have been shown to reduce compliance for other drugs, this is the first study to show an impact on such a crucial

drug where mortality can be so directly at stake," said Alfred Neugut, MD, the Myron M. Studner Professor of Cancer Research at Columbia's College of Physician and Surgeons and professor of epidemiology at the Mailman School of Public Health.

Provided by Columbia University

Citation: Higher co-payments increase chance of early discontinuation of breast cancer therapy (2010, December 11) retrieved 26 April 2024 from <https://medicalxpress.com/news/2010-12-higher-co-payments-chance-early-discontinuation.html>

This document is subject to copyright. Apart from any fair dealing for the purpose of private study or research, no part may be reproduced without the written permission. The content is provided for information purposes only.